bioNMER

First patient injected With cancer therapeutic Tribody CBA-1535 in a Phase I clinical trial

Chiome Bioscience Inc. announced that the first patient has been dosed with CBA-1535 in a Phase I clinical trial.
The first part of the trial will evaluate the safety tolerability, pharmacokinetics, and identification of biomarker for the solid tumor patients . In the expansion part, exploratory efficacy will be evaluated in combination with cancer immunotherapy agent Pembrolizuma.
This first in human study is conducted at National Cancer Center Hospital and Shizuoka Cancer Center (Japan).